ATE289506T1 - Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren - Google Patents

Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren

Info

Publication number
ATE289506T1
ATE289506T1 AT99961268T AT99961268T ATE289506T1 AT E289506 T1 ATE289506 T1 AT E289506T1 AT 99961268 T AT99961268 T AT 99961268T AT 99961268 T AT99961268 T AT 99961268T AT E289506 T1 ATE289506 T1 AT E289506T1
Authority
AT
Austria
Prior art keywords
tnf
inhibition
compositions containing
heparin
soluble
Prior art date
Application number
AT99961268T
Other languages
English (en)
Inventor
Dan Aderka
Englender Talma Eshed
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE289506T1 publication Critical patent/ATE289506T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT99961268T 1998-12-30 1999-12-30 Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren ATE289506T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12785198A IL127851A0 (en) 1998-12-30 1998-12-30 Inhibition of TNF activity
PCT/IL1999/000709 WO2000040225A2 (en) 1998-12-30 1999-12-30 Inhibition of tnf activity

Publications (1)

Publication Number Publication Date
ATE289506T1 true ATE289506T1 (de) 2005-03-15

Family

ID=11072323

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99961268T ATE289506T1 (de) 1998-12-30 1999-12-30 Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren

Country Status (12)

Country Link
US (1) US6608044B1 (de)
EP (1) EP1058544B1 (de)
JP (1) JP2002534375A (de)
AT (1) ATE289506T1 (de)
AU (1) AU780203B2 (de)
CA (1) CA2322229C (de)
DE (1) DE69923832T2 (de)
DK (1) DK1058544T3 (de)
ES (1) ES2237959T3 (de)
IL (2) IL127851A0 (de)
PT (1) PT1058544E (de)
WO (1) WO2000040225A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1192963A4 (de) * 2000-04-05 2004-08-25 Toray Industries Adsorbentien für proteine der gruppe high mobility protein und säule zum reinigen von körperflüssigkeiten
MXPA03004965A (es) * 2000-12-16 2003-09-25 Aventis Pharma Gmbh El uso de heparina de bajo peso molecular para el tratamiento de osteoartrosis.
CA2484604C (en) 2002-05-03 2011-08-02 Massachusetts Institute Of Technology .delta. 4,5 glycuronidase and uses thereof
US7307361B1 (en) 2006-11-13 2007-12-11 Drs Power & Control Technologies, Inc. Medium voltage power converter formed using low voltage drives
US7576604B2 (en) * 2006-12-15 2009-08-18 Bin Xu All-digital class-D audio amplifier
WO2009141821A1 (en) * 2008-05-20 2009-11-26 Crystal Clear Partnership Separation of polysaccharides by charge density gradient
WO2010003766A2 (en) * 2008-06-17 2010-01-14 Apogenix Gmbh Multimeric tnf receptors
WO2010013231A2 (en) * 2008-07-29 2010-02-04 Yeda Research And Development Co. Ltd. Modulation of coagulation factors and effectors of same for control of transplant organ size

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
CA2102207A1 (en) * 1991-05-02 1992-11-03 Irun R. Cohen Compositions for the prevention and/or treatment of patholigical processes
NZ256293A (en) * 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
JPH09509646A (ja) * 1993-07-30 1997-09-30 ケネディー インスティチュート オブ リューマトロジー 多発性硬化症を治療する方法
DE4435612A1 (de) * 1994-10-05 1996-04-11 Braun Melsungen Ag Verfahren zur simultanen Entfernung von Tumor-Nekrose-Faktor alpha und bakteriellen Lipopolysacchariden aus einer wäßrigen Flüssigkeit
AUPN673995A0 (en) * 1995-11-22 1995-12-14 Down Hole Technologies Pty Ltd A sleeve for orientating a tool
US6623472B1 (en) * 1997-08-16 2003-09-23 Orthogen Gentechnologic. Gmbh Method for inducing therapeutically-effective proteins

Also Published As

Publication number Publication date
CA2322229C (en) 2008-05-06
EP1058544A1 (de) 2000-12-13
JP2002534375A (ja) 2002-10-15
DE69923832D1 (de) 2005-03-31
AU1796100A (en) 2000-07-24
WO2000040225A2 (en) 2000-07-13
CA2322229A1 (en) 2000-07-13
WO2000040225A3 (en) 2000-09-21
IL127851A0 (en) 1999-10-28
PT1058544E (pt) 2005-04-29
IL138024A (en) 2006-09-05
AU780203B2 (en) 2005-03-10
DE69923832T2 (de) 2005-12-29
US6608044B1 (en) 2003-08-19
DK1058544T3 (da) 2005-03-14
ES2237959T3 (es) 2005-08-01
EP1058544B1 (de) 2005-02-23

Similar Documents

Publication Publication Date Title
UA41316C2 (uk) Трициклічні похідні піролу і фармацевтичний препарат
IL147852A0 (en) Chemokine receptor antagonists and pharmaceutical compositions containing the same
EP0513702A3 (de) Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie
UA26303A1 (uk) Фармацевтичhа композиція, яка має імуhосупресорhу та аhтимікробhу активhість
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
DK0902789T3 (da) Androstenderivater
IL137266A0 (en) Heterocyclic chemokine receptor antagonists and pharmaceutical compositions containing the same
ATE289506T1 (de) Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
WO2000030425A3 (en) Method of using pon-1 to decrease atheroma formation
IL126175A0 (en) Method or treating heart failure with endothelin antagonists and pharmaceutical compositions containing the same
BR0010092A (pt) Composto, preparação farmacêutica para a administração oral ou parenteral, uso de um composto, e, uso da preparação farmacêutica
LV10917A (lv) Bambuterina pielietojums lipidu saturu pazeminosu farmaceitisku kompoziciju pagatavosanai
ZA947401B (en) Use of partially methylated beta-cyclodextrins as absorption promoters in the preparation of pharmaceutical compositions for the transcutaneous administration of active principles
ITMI911445A1 (it) Impiego di derivati fosfolipidici per la preparazione di composizioni farmaceutiche aventi attivita' immunosoppressiva
ITMI913511A0 (it) Derivati dell'eserolina ad attivita' anticolinesterasica,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
BR9912117A (pt) Uso de estimulador de captação de glicose para reduzir a apoptose
ITMI911653A0 (it) Derivati dell'eseridina ad attivita' amticolinesterasi, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
ITMI922832A1 (it) DERIVATI DELL'ESEROLINA AD ATTIVITAy ANTICOLINESTERASICA, PROCEDIMENTO PER LA LORO PREPARAZIONE E COMPOSIZIONI FARMACEUTICHE CHE LI CONTENGONO.
FR2685204B1 (fr) Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine.
IT9047769A0 (it) Derivati 8-azaxantinici, loro sali fisiologicamente accettabili e loro composizioni farmaceutiche ad attivita' antibroncospastica.
ITMI913398A1 (it) Derivati dell'eserolina ad attivita' anticolinesterasica procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
IT8520150A0 (it) Nuovi derivati ad attivita'terapeutica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
IT8620713A0 (it) Nuovi derivati ad attivita'terapeutica, procedimento per la loro prepazione e relative compisizioni farmaceutiche.
ITRM910829A0 (it) Derivati dell'ipoxantina dotati di attivita' immunomodulante e composizioni farmaceutiche che li contengono

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1058544

Country of ref document: EP

REN Ceased due to non-payment of the annual fee